• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
PublishDashboard
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI employees
    Legal
    Terms of usePrivacy policyCookie policy

    B. Riley Securities reiterated coverage on Novavax with a new price target

    1/9/23 10:51:04 AM ET
    $NVAX
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care
    Get the next $NVAX alert in real time by email
    B. Riley Securities reiterated coverage of Novavax with a rating of Buy and set a new price target of $37.00 from $74.00 previously
    Get the next $NVAX alert in real time by email

    Chat with this insight

    Save time and jump to the most important pieces.

    Recent Analyst Ratings for
    $NVAX

    DatePrice TargetRatingAnalyst
    6/17/2025$6.00Sell
    Citigroup
    2/28/2025$19.00Buy
    BTIG Research
    7/30/2024$8.00Neutral → Underweight
    JP Morgan
    5/10/2024$4.00 → $12.00Underperform → Neutral
    BofA Securities
    5/10/2024Underweight → Neutral
    JP Morgan
    8/9/2023$15.00Neutral → Buy
    B. Riley Securities
    4/20/2023$55.00 → $10.00Outperform → Market Perform
    TD Cowen
    3/1/2023$29.00 → $10.00Buy → Neutral
    B. Riley Securities
    More analyst ratings

    $NVAX
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    See more
    • Director Mcglynn Margaret G converted options into 10,420 shares, increasing direct ownership by 69% to 25,588 units (SEC Form 4)

      4 - NOVAVAX INC (0001000694) (Issuer)

      6/16/25 4:10:45 PM ET
      $NVAX
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • Director Alton Gregg H converted options into 10,420 shares, increasing direct ownership by 57% to 28,805 units (SEC Form 4)

      4 - NOVAVAX INC (0001000694) (Issuer)

      6/16/25 4:09:43 PM ET
      $NVAX
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • Director King Rachel K. converted options into 10,420 shares, increasing direct ownership by 71% to 25,190 units (SEC Form 4)

      4 - NOVAVAX INC (0001000694) (Issuer)

      6/13/25 9:41:35 PM ET
      $NVAX
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care